Nuvectis Pharma, Inc.(NVCT)

Biotechnology · Fort Lee, NJ

$20.09-1.30 (-6.09%)

Delayed quote: Oct 6, 2026, 2:24 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T18:27:46.048Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:46.048Z.

Quote observation: 2026-10-06T18:24:51.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 533,024,001
TTM operating cash flow · period ending 2026-06-30: -19,510,000

FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NVCT Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

NVCT Competitors' Price/OCF Ratio

NVCT

Nuvectis Pharma, Inc.

Current

Market Cap

$533.02M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHAT

Phathom Pharmaceuticals, Inc.

vs NVCT

Market Cap

$533.82M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs NVCT

Market Cap

$535.95M

Price/OCF Ratio

27.36

TTM Avg

30.64

3Y Avg

39.07

5Y Avg

39.07

PROK

ProKidney Corp.

vs NVCT

Market Cap

$536.32M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs NVCT

Market Cap

$526.55M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs NVCT

Market Cap

$525.52M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLSM

BlossomHill Therapeutics, Inc.

vs NVCT

Market Cap

$524.04M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STTK

Shattuck Labs, Inc.

vs NVCT

Market Cap

$541.32M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs NVCT

Market Cap

$520.26M

Price/OCF Ratio

N/A

TTM Avg

0.26

3Y Avg

0.26

5Y Avg

0.26

MNPR

Monopar Therapeutics Inc.

vs NVCT

Market Cap

$547.38M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Nuvectis Pharma, Inc. (NVCT)	$533.02M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$533.82M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$535.95M	27.36	30.64	39.07	39.07
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$526.55M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$525.52M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$524.04M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$541.32M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$520.26M	N/A	0.26	0.26	0.26
Monopar Therapeutics Inc. (MNPR)vs ›	$547.38M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

NVCT Price/OCF Ratio Metrics

NVCT Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics